Kala Pharmaceuticals, Inc. (Kala) is a clinical stage pharmaceutical company focused on innovative nanoparticle-based treatments for ocular diseases affecting both front and back of the eye. Kala leverages its proprietary mucus-penetrating particle (MPP) technology to develop topical ophthalmic formulations with enhanced delivery into ocular tissue by facilitating penetration through the tear film mucus.
Founded by leaders in the fields of nanomedicine and biopharmaceutical engineering and backed by leading life sciences investors, Kala utilizes a multi-disciplinary scientific approach and internal expertise in all stages of pharmaceutical development with the goal of translating its MPP technology into products that seek to address unmet therapeutic needs.
Kala’s lead program, a shelf-stable MPP nanosuspension of an ophthalmic corticosteroid, is in clinical trials for the treatment of post-surgical ocular inflammation and dry eye disease. Kala is also advancing its novel, small molecule receptor tyrosine kinase inhibitor (RTKi) program as a potential topical treatment of wet age-related macular degeneration (AMD).
Beyond ophthalmology, Kala’s MPP technology has potential applications in women’s reproductive health, respiratory and gastrointestinal diseases, and other indications.
The name Kala was inspired by the famous Kalalau trail, a hiking trail on the island of Kauai, Hawaii. This trail is not only notable for its strenuous path and terrain that is difficult to traverse but also known for its unsurpassed beauty.